Endocrine role of bone in the regulation of energy metabolism

Abstract

Bone mainly functions as a supportive framework for the whole body and is the major regulator of calcium homeostasis and hematopoietic function. Recently, an increasing number of studies have characterized the significance of bone as an endocrine organ, suggesting that bone-derived factors regulate local bone metabolism and metabolic functions. In addition, these factors can regulate global energy homeostasis by altering insulin sensitivity, feeding behavior, and adipocyte commitment. These findings may provide a new pathological mechanism for related metabolic diseases or be used in the diagnosis, treatment, and prevention of metabolic diseases such as osteoporosis, obesity, and diabetes mellitus. In this review, we summarize the regulatory effect of bone and bone-derived factors on energy metabolism and discuss directions for future research.

References

[1] Sommerfeldt DW, Rubin CT. Biology of bone and how it orchestrates the form and function of the skeleton. Eur. Spine J., 2001, 10: S86-S95

[2] Bronner F. Extracellular and intracellular regulation of calcium homeostasis. Sci. World J., 2001, 1: 919-925

[3] Askmyr M, Quach J, Purton LE. Effects of the bone marrow microenvironment on hematopoietic malignancy. Bone, 2011, 48: 115-120

[4] Abarrategi A et al. Modeling the human bone marrow niche in mice: from host bone marrow engraftment to bioengineering approaches. J. Exp. Med., 2018, 215: 729-743

[5] Kajimura D et al. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab., 2013, 17: 901-915

[6] Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab., 2006, 4: 341-348

[7] Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia, 2017, 60: 1163-1169

[8] Andrukhova O, Streicher C, Zeitz U, Erben RG. Fgf23 and parathyroid hormone signaling interact in kidney and bone. Mol. Cell Endocrinol., 2016, 436: 224-239

[9] Cai X, Xing J, Long CL, Peng Q, Humphrey MB. DOK3 modulates bone remodeling by negatively regulating osteoclastogenesis and positively regulating osteoblastogenesis. J. Bone Min. Res., 2017, 32: 2207-2218

[10] Kalbasi Anaraki P et al. Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-κB pathway in osteoclasts. J. Bone Min. Res., 2015, 30: 379-388

[11] Matsuoka K, Park KA, Ito M, Ikeda K, Takeshita S. Osteoclast-derived complement component 3a stimulates osteoblast differentiation. J. Bone Min. Res., 2014, 29: 1522-1530

[12] Shimada T et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Min. Res., 2004, 19: 429-435

[13] Gupte AA et al. Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology, 2014, 155: 4697-4705

[14] Du J et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine, 2016, 53: 701-709

[15] Mizokami A et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS ONE, 2013, 8

[16] Otani T et al. Signaling pathway for adiponectin expression in adipocytes by osteocalcin. Cell Signal, 2015, 27: 532-544

[17] Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat. Rev. Endocrinol., 2013, 9: 43-55

[18] Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol. Rev., 1989, 69: 990-1047

[19] Ducy P et al. Increased bone formation in osteocalcin-deficient mice. Nature, 1996, 382: 448-452

[20] Ishida M, Amano S. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. J. Bone Min. Metab., 2004, 22: 415-429

[21] Nikel O, Poundarik AA, Bailey S, Vashishth D. Structural role of osteocalcin and osteopontin in energy dissipation in bone. J. Biomech., 2018, 80: 45-52

[22] Hu CM et al. High glucose triggers nucleotide imbalance through O-GlcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells. Cell Metab., 2019, 29: 1334-1349.e10

[23] Lee NK et al. Endocrine regulation of energy metabolism by the skeleton. Cell, 2007, 130: 456-469

[24] Malashkevich VN, Almo SC, Dowd TL. X-ray crystal structure of bovine 3 Glu-osteocalcin. Biochemistry, 2013, 52: 8387-8392

[25] Rached M-T et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J. Clin. Investig., 2010, 120: 357-368

[26] Guedes JAC, Esteves JV, Morais MR, Zorn TM, Furuya DT. Osteocalcin improves insulin resistance and inflammation in obese mice: Participation of white adipose tissue and bone. Bone, 2018, 115: 68-82

[27] Levinger I et al. The effects of muscle contraction and recombinant osteocalcin on insulin sensitivity ex vivo. Osteoporos. Int., 2016, 27: 653-663

[28] Lin X et al. Recombinant uncarboxylated osteocalcin per se enhances mouse skeletal muscle glucose uptake in both extensor digitorum longus and soleus muscles. Front Endocrinol., 2017, 8: 330

[29] Pi M et al. Evidence for osteocalcin binding and activation of GPRC6A in β-cells. Endocrinology, 2016, 157: 1866-1880

[30] Sanchez-Gurmaches J et al. Brown Fat AKT2 is a cold-induced kinase that stimulates ChREBP-mediated de novo lipogenesis to optimize fuel storage and thermogenesis. Cell Metab., 2018, 27: 195-209.e6

[31] Gao J et al. The PLC/PKC/Ras/MEK/Kv channel pathway is involved in uncarboxylated osteocalcin-regulated insulin secretion in rats. Peptides, 2016, 86: 72-79

[32] Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab., 2018, 27: 740-756

[33] Mizokami A et al. Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion. Bone, 2014, 69: 68-79

[34] Zhou B et al. Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway. Endocrinology, 2013, 154: 1055-1068

[35] Guo Q et al. Undercarboxylated osteocalcin reverts insulin resistance induced by endoplasmic reticulum stress in human umbilical vein endothelial cells. Sci. Rep., 2017, 7: 46

[36] Jung CH et al. The preventive effect of uncarboxylated osteocalcin against free fatty acid-induced endothelial apoptosis through the activation of phosphatidylinositol 3-kinase/Akt signaling pathway. Metabolism, 2013, 62: 1250-1257

[37] Kalucka J et al. Quiescent endothelial cells upregulate fatty acid β-oxidation for vasculoprotection via redox homeostasis. Cell Metab., 2018, 28: 881-894.e13

[38] Li X, Sun X, Carmeliet P. Hallmarks of endothelial cell metabolism in health and disease. Cell Metab., 2019, 30: 414-433

[39] Hill HS et al. Carboxylated and uncarboxylated forms of osteocalcin directly modulate the glucose transport system and inflammation in adipocytes. Horm. Metab. Res., 2014, 46: 341-347

[40] Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J. Bone Min. Res., 2011, 26: 677-680

[41] De Toni L et al. Osteocalcin, a bone-derived hormone with important andrological implications. Andrology, 2017, 5: 664-670

[42] Otani T et al. Osteocalcin triggers Fas/FasL-mediated necroptosis in adipocytes via activation of p300. Cell Death Dis., 2018, 9: 1194

[43] Li Q et al. T Cell factor 7 (TCF7)/TCF1 feedback controls osteocalcin signaling in brown adipocytes independent of the Wnt/β-catenin pathway. Mol. Cell Biol., 2018, 38: e00562-17

[44] Mottillo EP, Ramseyer VD, Granneman JG. SERCA2b cycles its way to UCP1-independent thermogenesis in beige fat. Cell Metab., 2018, 27: 7-9

[45] Deppermann, C. et al. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets. J. Exp. Med. 217, e20190723 (2020).

[46] Wellendorph P, Bräuner-Osborne H. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene, 2004, 335: 37-46

[47] Ackerman SD et al. GPR56/ADGRG1 regulates development and maintenance of peripheral myelin. J. Exp. Med., 2018, 215: 941-961

[48] Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J. Bone Min. Res., 2011, 26: 1680-1683

[49] Fu A, Eberhard CE, Screaton RA. Role of AMPK in pancreatic beta cell function. Mol. Cell Endocrinol., 2013, 366: 127-134

[50] Ardestani A, Lupse B, Kido Y, Leibowitz G, Maedler K. mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells. Cell Metab., 2018, 27: 314-331

[51] Karmaus PWF et al. Critical roles of mTORC1 signaling and metabolic reprogramming for M-CSF-mediated myelopoiesis. J. Exp. Med., 2017, 214: 2629-2647

[52] Lin SC, Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell Metab., 2018, 27: 299-313

[53] Pi M, Nishimoto SK, Quarles LD. GPRC6A: Jack of all metabolism (or master of none). Mol. Metab., 2016, 6: 185-193

[54] Diegel CR et al. An osteocalcin-deficient mouse strain without endocrine abnormalities. PLoS Genet., 2020, 16

[55] Choi HJ et al. Vitamin K2 supplementation improves insulin sensitivity via osteocalcin metabolism: a placebo-controlled trial. Diabetes Care, 2011, 34

[56] Pollock NK et al. Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J. Clin. Endocrinol. Metab., 2011, 96: E1092-E1099

[57] Choudhury AB, Sarkar PD, Sakalley DK, Petkar SB. Role of adiponectin in mediating the association of osteocalcin with insulin resistance and type 2 diabetes: a cross sectional study in pre- and post-menopausal women. Arch. Physiol. Biochem., 2014, 120: 73-79

[58] Martin TJ, Sims NA. RANKL/OPG; Critical role in bone physiology. Rev. Endocr. Metab. Disord., 2015, 16: 131-139

[59] Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319

[60] Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther., 2007, 9: S1

[61] Nakashima T et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med., 2011, 17: 1231-1234

[62] Chen C et al. MiR-503 regulates osteoclastogenesis via targeting RANK. J. Bone Min. Res., 2014, 29: 338-347

[63] Kondegowda NG et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway. Cell Metab., 2015, 22: 77-85

[64] Sacco F et al. Phosphoproteomics reveals the GSK3-PDX1 axis as a key pathogenic signaling node in diabetic islets. Cell Metab., 2019, 29: 1422-1432.e3

[65] Musialik K, Szulińska M, Hen K, Skrypnik D, Bogdański P. The relation between osteoprotegerin, inflammatory processes, and atherosclerosis in patients with metabolic syndrome. Eur. Rev. Med Pharm. Sci., 2017, 21: 4379-4385

[66] Monseu M et al. Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes Metab., 2016, 42: 364-367

[67] Cappel DA et al. Pyruvate-carboxylase-mediated anaplerosis promotes antioxidant capacity by sustaining TCA cycle and redox metabolism in liver. Cell Metab., 2019, 29: 1291-1305.e8

[68] Bilgir O et al. Relationship between insulin resistance, hs-CRP, and body fat and serum osteoprotegerin/RANKL in prediabetic patients. Minerva Endocrinol., 2018, 43: 19-26

[69] Suliburska J et al. The association of insulin resistance with serum osteoprotegerin in obese adolescents. J. Physiol. Biochem, 2013, 69: 847-853

[70] Stekovic S et al. Alternate day fasting improves physiological and molecular markers of aging in healthy, non-obese humans. Cell Metab., 2019, 30: 462-476.e6

[71] Ou D et al. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia, 2002, 45: 1678-1688

[72] Chamoux E, Houde N, L’Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J. Cell Physiol., 2008, 216: 536-542

[73] Vaccarezza M, Bortul R, Fadda R, Zweyer M. Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats. Med. Chem., 2007, 3: 387-391

[74] Knudsen JG, Rorsman P. β cell dysfunction in type 2 diabetes: drained of energy? Cell Metab., 2019, 29: 1-2

[75] Schrader J et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia, 2007, 50: 1243-1247

[76] Taylor R et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab., 2018, 28: 547-556.e3

[77] Lacombe J, Karsenty G, Ferron M. In vivo analysis of the contribution of bone resorption to the control of glucose metabolism in mice. Mol. Metab., 2013, 2: 498-504

[78] Niu Y et al. Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: a case-control study in China. Metabolism, 2016, 65: 475-481

[79] Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab., 2018, 27: 22-41

[80] Ayaz T et al. The relation between carotid intima media thickness and serum osteoprotegerin levels in nonalcoholic fatty liver disease. Metab. Syndr. Relat. Disord., 2014, 12: 283-289

[81] D’Amelio P, Isaia G, Fau -, Isaia GC, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev. Cardiovasc Ther., 2006, 4: 801-811

[82] Kiechl S et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med., 2013, 19: 358-363

[83] Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93: 165-176

[84] Fan Y et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab., 2017, 25: 661-672

[85] Franzén A, Heinegård D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J., 1985, 232: 715-724

[86] Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett., 2013, 331: 11-17

[87] Luukkonen J et al. Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. Histochem. Cell Biol., 2019, 151: 475-487

[88] Oldberg A, Franzén A, Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl Acad. Sci. USA, 1986, 83: 8819-8823

[89] Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev., 2008, 19: 333-345

[90] Ge Q et al. Osteopontin regulates macrophage activation and osteoclast formation in hypertensive patients with vascular calcification. Sci. Rep., 2017, 7: 40253

[91] Ishijima M et al. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J. Exp. Med., 2001, 193: 399-404

[92] Chen Q et al. An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal. Stem Cells, 2014, 32: 327-337

[93] Chapman J et al. Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS ONE, 2010, 5

[94] Inoue H et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med., 2004, 10: 168-174

[95] Kiefer FW et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes, 2010, 59: 935-946

[96] Kon S et al. Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin. J. Exp. Med., 2008, 205: 25-33

[97] Nuñez-Garcia M et al. Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. J. Lipid Res., 2017, 58: 1903-1915

[98] Zeyda M et al. Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology, 2011, 152: 2219-2227

[99] Arafat HA et al. Osteopontin protects the islets and beta-cells from interleukin-1 beta-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology, 2007, 148: 575-584

[100] Ma D, Leulier F. A new transkingdom dimension to NO signaling. Cell Metab., 2019, 29: 513-515

[101] Wendt A et al. Osteopontin affects insulin vesicle localization and Ca2+ homeostasis in pancreatic beta cells from female mice. PLoS ONE, 2017, 12

[102] Ahmad R et al. Interaction of osteopontin with IL-18 in obese individuals: implications for insulin resistance. PLoS ONE, 2013, 8

[103] Barchetta I et al. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur. J. Endocrinol., 2016, 174: 187-192

[104] Carbone F et al. Serum levels of osteopontin predict diabetes remission after bariatric surgery. Diabetes Metab., 2019, 45: 356-362

[105] Kiefer FW et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology, 2008, 149: 1350-1357

[106] Talat MA et al. The role of osteopontin in the pathogenesis and complications of type 1 diabetes mellitus in children. J. Clin. Res. Pediatr. Endocrinol., 2016, 8: 399-404

[107] Lee H et al. Beta cell dedifferentiation induced by IRE1α deletion prevents type 1 diabetes. Cell Metab., 2020, 31: 822-836.e5

[108] Marciano R et al. Association of alleles at polymorphic sites in the Osteopontin encoding gene in young type 1 diabetic patients. Clin. Immunol., 2009, 131: 84-91

[109] Warshauer JT, Bluestone JA, Anderson MS. New frontiers in the treatment of type 1 diabetes. Cell Metab., 2020, 31: 46-61

[110] You JS et al. Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans. Mol. Med. Rep., 2013, 8: 579-584

[111] Israel DI et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors, 1996, 13: 291-300

[112] Urist MR. Bone: formation by autoinduction. Science, 1965, 150: 893-899

[113] Celeste AJ et al. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc. Natl Acad. Sci. USA, 1990, 87: 9843-9847

[114] Brazil DP, Church RH, Surae S, Godson C, Martin F. BMP signalling: agony and antagony in the family. Trends Cell Biol., 2015, 25: 249-264

[115] Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors, 2004, 22: 233-241

[116] Nohno T et al. Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heteromeric complexes with bone morphogenetic protein type I receptors. J. Biol. Chem., 1995, 270: 22522-22526

[117] ten Dijke P, Miyazono K, Heldin CH. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr. Opin. Cell Biol., 1996, 8: 139-145

[118] Ebara S, Nakayama K. Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine, 2002, 27: S10-S15

[119] Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature, 1997, 390: 465-471

[120] Wang P et al. Combined inhibition of DYRK1A, SMAD, and trithorax pathways synergizes to induce robust replication in adult human beta cells. Cell Metab., 2019, 29: 638-652.e5

[121] Lu Q et al. GDF11 inhibits bone formation by activating Smad2/3 in bone marrow mesenchymal stem cells. Calcif. Tissue Int., 2016, 99: 500-509

[122] Guo X, Wang X-F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res., 2009, 19: 71-88

[123] Lowery JW, Rosen V. The BMP pathway and its inhibitors in the skeleton. Physiol. Rev., 2018, 98: 2431-2452

[124] Yang M et al. MiR-497∼195 cluster regulates angiogenesis during coupling with osteogenesis by maintaining endothelial Notch and HIF-1α activity. Nat. Commun., 2017, 8

[125] Maeda Y, Tsuji K, Nifuji A, Noda M. Inhibitory helix-loop-helix transcription factors Id1/Id3 promote bone formation in vivo. J. Cell Biochem., 2004, 93: 337-344

[126] Peng Y et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem., 2004, 279: 32941-32949

[127] Elsen M et al. BMP4 and BMP7 induce the white-to-brown transition of primary human adipose stem cells. Am. J. Physiol. Cell Physiol., 2014, 306: C431-C440

[128] Fabbiano S et al. Caloric restriction leads to browning of white adipose tissue through type 2 immune signaling. Cell Metab., 2016, 24: 434-446

[129] Gustafson B et al. BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes, 2015, 64: 1670-1681

[130] Hata K et al. Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol. Biol. Cell, 2003, 14: 545-555

[131] Hino J et al. Overexpression of bone morphogenetic protein-3b (BMP-3b) in adipose tissues protects against high-fat diet-induced obesity. Int J. Obes., 2017, 41: 483-488

[132] Hoffmann JM et al. BMP4 gene therapy in mature mice reduces BAT activation but protects from obesity by browning subcutaneous adipose tissue. Cell Rep., 2017, 20: 1038-1049

[133] Huang H et al. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc. Natl Acad. Sci. USA, 2009, 106: 12670-12675

[134] Kim S, Choe S, Lee DK. BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity. Biochim. Biophys. Acta, 2016, 1862: 1237-1246

[135] Tseng YH et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature, 2008, 454: 1000-1004

[136] Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors, 1993, 9: 57-71

[137] Whittle AJ et al. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell, 2012, 149: 871-885

[138] Wang QA et al. Reversible de-differentiation of mature white adipocytes into preadipocyte-like precursors during lactation. Cell Metab., 2018, 28: 282-288.e3

[139] Li CJ et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J. Clin. Investig., 2015, 125: 1509-1522

[140] Zhang R et al. The role of microRNAs in adipocyte differentiation. Front. Med., 2013, 7: 223-230

[141] Chattopadhyay T, Singh RR, Gupta S, Surolia A. Bone morphogenetic protein-7 (BMP-7) augments insulin sensitivity in mice with type II diabetes mellitus by potentiating PI3K/AKT pathway. Biofactors, 2017, 43: 195-209

[142] Luo Y et al. Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance. Clin. Sci., 2017, 131: 239-246

[143] Schreiber I et al. BMPs as new insulin sensitizers: enhanced glucose uptake in mature 3T3-L1 adipocytes via PPARγ and GLUT4 upregulation. Sci. Rep., 2017, 7: 17192

[144] Yang M et al. Role of bone morphogenetic protein-9 in the regulation of glucose and lipid metabolism. FASEB J., 2019, 33: 10077-10088

[145] Wang X et al. New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it. Lipids Health Dis., 2017, 16: 70

[146] Hodgson J et al. Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med., 2020, 201: 575-585

[147] Vukicevic S, Helder MN, Luyten FP. Developing human lung and kidney are major sites for synthesis of bone morphogenetic protein-3 (osteogenin). J. Histochem. Cytochem., 1994, 42: 869-875

[148] Kokubu, N., Tsujii, M., Akeda, K., Iino, T. & Sudo, A. BMP-7/Smad expression in dedifferentiated Schwann cells during axonal regeneration and upregulation of endogenous BMP-7 following administration of PTH (1–34). J. Orthop. Surg. 26, 2309499018812953 (2018).

[149] Yamashita K, Mikawa S, Sato K. BMP3 expression in the adult rat CNS. Brain Res., 2016, 1643: 35-50

[150] Desroches-Castan A et al. Differential consequences of Bmp9 deletion on sinusoidal endothelial cell differentiation and liver fibrosis in 129/Ola and C57BL/6 mice. Cells, 2019, 8: 1079

[151] Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 2009, 8: 235-253

[152] Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev., 2015, 29: 1463-1486

[153] Luo Y, Ye S, Li X, Lu W. Emerging structure-function paradigm of endocrine FGFs in metabolic diseases. Trends Pharm. Sci., 2019, 40: 142-153

[154] Peng M et al. Developments in the study of gastrointestinal microbiome disorders affected by FGF19 in the occurrence and development of colorectal neoplasms. J. Cell Physiol., 2020, 235: 4060-4069

[155] Geller S et al. Tanycytes regulate lipid homeostasis by sensing free fatty acids and signaling to key hypothalamic neuronal populations via FGF21 secretion. Cell Metab., 2019, 30: 833-844.e7

[156] Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta., 2000, 1492: 203-206

[157] Erben RG. Pleiotropic actions of FGF23. Toxicol. Pathol., 2017, 45: 904-910

[158] Clinkenbeard EL et al. Conditional deletion of murine Fgf23: interruption of the normal skeletal responses to phosphate challenge and rescue of genetic hypophosphatemia. J. Bone Miner. Res., 2016, 31: 1247-1257

[159] Hu MC et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J., 2010, 24: 3438-3450

[160] Strewler GJ. Untangling klotho’s role in calcium homeostasis. Cell Metab., 2007, 6: 93-95

[161] Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab., 2012, 16: 693-705

[162] Komaba H et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int., 2017, 92: 599-611

[163] Rhee Y et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone, 2011, 49: 636-643

[164] Kaludjerovic J et al. Klotho expression in long bones regulates FGF23 production during renal failure. FASEB J., 2017, 31: 2050-2064

[165] Kurosu H et al. Suppression of aging in mice by the hormone Klotho. Science, 2005, 309: 1829-1833

[166] Hesse M, Fröhlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol., 2007, 26: 75-84

[167] López I et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int., 2011, 80: 475-482

[168] Singh S et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int., 2016, 90: 985-996

[169] Ito N et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol. Cell. Endocrinol., 2015, 399: 208-218

[170] Mirza MAI et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb. Vasc. Biol., 2011, 31: 219-227

[171] Aljohani A et al. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice. J. Biol. Chem., 2019, 294: 19475-19485

[172] Chen Y, Lu J, Nemati R, Plank LD, Murphy R. Acute changes of bile acids and FGF19 after sleeve gastrectomy and Roux-en-Y gastric bypass. Obes. Surg., 2019, 29: 3605-3621

[173] Lan T et al. FGF19, FGF21, and an FGFR1/β-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab., 2017, 26: 709-718.e3

[174] Mosialou I et al. MC4R-dependent suppression of appetite by bone-derived lipocalin 2. Nature, 2017, 543: 385-390

[175] Zhang J et al. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol. Endocrinol., 2008, 22: 1416-1426

[176] Flower DR. Beyond the superfamily: the lipocalin receptors. Biochim Biophys. Acta, 2000, 1482: 327-336

[177] Jha MK et al. Diverse functional roles of lipocalin-2 in the central nervous system. Neurosci. Biobehav Rev., 2015, 49: 135-156

[178] Adriaenssens AE et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab., 2019, 30: 987-996.e6

[179] Liu H et al. Transgenic mice expressing green fluorescent protein under the control of the melanocortin-4 receptor promoter. J. Neurosci., 2003, 23: 7143-7154

[180] Guo H et al. Lipocalin 2, a regulator of retinoid homeostasis and retinoid-mediated thermogenic activation in adipose tissue. J. Biol. Chem., 2016, 291: 11216-11229

[181] Guo H et al. Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes, 2010, 59: 1376-1385

[182] Yu B et al. PGC-1α controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. Cell Stem Cell, 2018, 23: 193-209.e5

[183] Zhang Y et al. Lipocalin 2 regulates brown fat activation via a nonadrenergic activation mechanism. J. Biol. Chem., 2014, 289: 22063-22077

[184] Kamble PG et al. Lipocalin 2 produces insulin resistance and can be upregulated by glucocorticoids in human adipose tissue. Mol. Cell Endocrinol., 2016, 427: 124-132

[185] Capulli M et al. A complex role for lipocalin 2 in bone metabolism: global ablation in mice induces osteopenia caused by an altered energy metabolism. J. Bone Min. Res., 2018, 33: 1141-1153

[186] Wang W et al. Elevated serum lipocalin 2 levels are associated with indexes of both glucose and bone metabolism in type 2 diabetes mellitus. Endokrynol. Pol., 2018, 69: 276-282

[187] van Bezooijen RL et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med., 2004, 199: 805-814

[188] Collette NM et al. Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. Dev. Biol., 2013, 383: 90-105

[189] Winkler DG et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J., 2003, 22: 6267-6276

[190] Li C et al. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression. Ann. N. Y Acad. Sci., 2016, 1364: 62-73

[191] Bullock WA et al. Lrp4 mediates bone homeostasis and mechanotransduction through interaction with sclerostin in vivo. iScience, 2019, 20: 205-215

[192] Liu W et al. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice. Open Biol., 2019, 9: 180262

[193] Stolina M et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone, 2014, 67: 305-313

[194] Fijalkowski I et al. A novel domain-specific mutation in a sclerosteosis patient suggests a role of LRP4 as an anchor for sclerostin in human bone. J. Bone Min. Res., 2016, 31: 874-881

[195] Haynes KR et al. Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. BMC Musculoskelet. Disord., 2015, 16: 368

[196] Koide M et al. Bone formation is coupled to resorption via suppression of sclerostin expression by osteoclasts. J. Bone Min. Res., 2017, 32: 2074-2086

[197] Faienza MF et al. High sclerostin and dickkopf-1 (DKK-1) serum levels in children and adolescents with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab., 2017, 102: 1174-1181

[198] Hie M, Iitsuka N, Otsuka T, Tsukamoto I. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J. Mol. Med., 2011, 28: 455-462

[199] Daniele G et al. Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism. Diabetes Care, 2015, 38: 1509-1517

[200] Yu OHY et al. The association between sclerostin and incident type 2 diabetes risk: a cohort study. Clin. Endocrinol., 2017, 86: 520-525

[201] Kim SP et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc. Natl Acad. Sci. USA, 2017, 114: E11238-E11247

[202] Fulzele K et al. Osteocyte-secreted Wnt signaling inhibitor sclerostin contributes to beige adipogenesis in peripheral fat depots. J. Bone Min. Res., 2017, 32: 373-384

[203] Hofmann S, Bellmann-Sickert K, Beck-Sickinger AG. Chemical modification of neuropeptide Y for human Y1 receptor targeting in health and disease. Biol. Chem., 2019, 400: 299-311

[204] Kawakami Y. Neuropeptide Y. Nihon. Rinsho., 2005, 63: S421-S424

[205] Cedernaes J et al. Transcriptional basis for rhythmic control of hunger and metabolism within the AgRP neuron. Cell Metab., 2019, 29: 1078-1091.e5

[206] Ip CK et al. Amygdala NPY circuits promote the development of accelerated obesity under chronic stress conditions. Cell Metab., 2019, 30: 111-128.e6

[207] Krashes MJ et al. An excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger. Nature, 2014, 507: 238-242

[208] Chen Z. Temporal control of appetite by AgRP Clocks. Cell Metab., 2019, 29: 1022-1023

[209] Makhmutova M, Rodriguez-Diaz R, Caicedo A. A nervous breakdown that may stop autoimmune diabetes. Cell Metab., 2020, 31: 215-216

[210] Lee DY et al. Neuropeptide Y mitigates ER stress-induced neuronal cell death by activating the PI3K-XBP1 pathway. Eur. J. Cell Biol., 2018, 97: 339-348

[211] Fetissov SO, Kopp J, Hökfelt T. Distribution of NPY receptors in the hypothalamus. Neuropeptides, 2004, 38: 175-188

[212] Huang L et al. Actions of NPY, and its Y1 and Y2 receptors on pulsatile growth hormone secretion during the fed and fasted state. J. Neurosci., 2014, 34: 16309-16319

[213] Park MH et al. Neuropeptide Y induces hematopoietic stem/progenitor cell mobilization by regulating matrix metalloproteinase-9 activity through Y1 receptor in osteoblasts. Stem Cells, 2016, 34: 2145-2156

[214] Shin MK et al. Elevated pentraxin 3 in obese adipose tissue promotes adipogenic differentiation by activating neuropeptide Y signaling. Front. Immunol., 2018, 9: 1790

[215] Yang K, Guan H, Arany E, Hill DJ, Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J., 2008, 22: 2452-2464

[216] Franklin ZJ et al. Islet neuropeptide Y receptors are functionally conserved and novel targets for the preservation of beta-cell mass. Diabetes Obes. Metab., 2018, 20: 599-609

[217] Khan D, Vasu S, Moffett RC, Irwin N, Flatt PR. Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival. Biochim. Biophys. Acta Gen. Subj., 2017, 1861: 749-758

[218] Loh K, Herzog H, Shi YC. Regulation of energy homeostasis by the NPY system. Trends Endocrinol. Metab., 2015, 26: 125-135

[219] Igwe JC et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J. Cell Biochem., 2009, 108: 621-630

[220] Wee NKY et al. Diet-induced obesity suppresses cortical bone accrual by a neuropeptide Y-dependent mechanism. Int J. Obes., 2018, 42: 1925-1938

[221] Wu J et al. Neuropeptide Y enhances proliferation and prevents apoptosis in rat bone marrow stromal cells in association with activation of the Wnt/β-catenin pathway in vitro. Stem Cell Res, 2017, 21: 74-84

[222] Wee NKY et al. Skeletal phenotype of the neuropeptide Y knockout mouse. Neuropeptides, 2019, 73: 78-88

[223] Lee NJ et al. NPY signalling in early osteoblasts controls glucose homeostasis. Mol. Metab., 2015, 4: 164-174

[224] Kronenberg HM. PTHrP and skeletal development. Ann. N. Y Acad. Sci., 2006, 1068: 1-13

[225] Wysolmerski JJ. Parathyroid hormone-related protein: an update. J. Clin. Endocrinol. Metab., 2012, 97: 2947-2956

[226] Dudeck J et al. Mast cells acquire MHCII from dendritic cells during skin inflammation. J. Exp. Med., 2017, 214: 3791-3811

[227] Miao D et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Investig., 2005, 115: 2402-2411

[228] Zhang X, Cheng Q, Wang Y, Leung PS, Mak KK. Hedgehog signaling in bone regulates whole-body energy metabolism through a bone-adipose endocrine relay mediated by PTHrP and adiponectin. Cell Death Differ., 2017, 24: 225-237

[229] Guthalu Kondegowda N et al. Parathyroid hormone-related protein enhances human ß-cell proliferation and function with associated induction of cyclin-dependent kinase 2 and cyclin E expression. Diabetes, 2010, 59: 3131-3138

[230] Horwitz MJ et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J. Clin. Endocrinol. Metab., 2010, 95: 1279-1287

[231] Bukowska J et al. Bone marrow adipocyte developmental origin and biology. Curr. Osteoporos. Rep., 2018, 16: 312-319

[232] Bhansali S et al. Effect of mesenchymal stem cells transplantation on glycaemic profile & their localization in streptozotocin induced diabetic Wistar rats. Indian J. Med. Res., 2015, 142: 63-71

[233] Bhansali S et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study. Stem Cells Dev., 2017, 26: 471-481

[234] Rydén M et al. Transplanted bone marrow-derived cells contribute to human adipogenesis. Cell Metab., 2015, 22: 408-417

[235] Goldberg EL, Dixit VD. Bone marrow: an immunometabolic refuge during energy depletion. Cell Metab., 2019, 30: 621-623

[236] Zhang J et al. Metabolism in pluripotent stem cells and early mammalian development. Cell Metab., 2018, 27: 332-338

[237] Liu J et al. Bone-derived exosomes. Curr. Opin. Pharm., 2017, 34: 64-69

[238] Kita S, Maeda N, Shimomura I. Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J. Clin. Investig., 2019, 129: 4041-4049

[239] Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol., 2013, 200: 373-383

[240] Guay C et al. Lymphocyte-derived exosomal micrornas promote pancreatic β cell death and may contribute to type 1 diabetes development. Cell Metab., 2019, 29: 348-361.e6

[241] Whitham M et al. Extracellular vesicles provide a means for tissue crosstalk during exercise. Cell Metab., 2018, 27: 237-251.e4

[242] Deng L et al. Osteoblast-derived microvesicles: a novel mechanism for communication between osteoblasts and osteoclasts. Bone, 2015, 79: 37-42

[243] Lyu H, Xiao Y, Guo Q, Huang Y, Luo X. The role of bone-derived exosomes in regulating skeletal metabolism and extraosseous diseases. Front. Cell Dev. Biol., 2020, 8: 89

[244] Sun W et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov., 2016, 2: 16015

[245] Yeo RWY et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev., 2013, 65: 336-341

[246] Huynh N et al. Characterization of regulatory extracellular vesicles from osteoclasts. J. Dent. Res, 2016, 95: 673-679

[247] Li D et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun., 2016, 7: 10872

[248] Mori MA, Ludwig RG, Garcia-Martin R, Brandão BB, Kahn CR. Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab., 2019, 30: 656-673

[249] Baglio SR et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther., 2015, 6: 127

[250] Su T et al. Bone marrow mesenchymal stem cells-derived exosomal MiR-29b-3p regulates aging-associated insulin resistance. ACS Nano, 2019, 13: 2450-2462

[251] Rong X et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway. Stem Cell Res. Ther., 2019, 10: 98

[252] AbuBakr N, Haggag T, Sabry D, Salem ZA. Functional and histological evaluation of bone marrow stem cell-derived exosomes therapy on the submandibular salivary gland of diabetic Albino rats through TGFβ/ Smad3 signaling pathway. Heliyon, 2020, 6

[253] Hotamisligil GS. Inflammation and metabolic disorders. Nature, 2006, 444: 860-867

[254] Malle EK et al. Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity. J. Exp. Med., 2015, 212: 1239-1254

[255] Lee A, Dixit VD. Energy sparing orexigenic inflammation of obesity. Cell Metab., 2017, 26: 10-12

[256] Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Investig., 2017, 127: 1-4

[257] Laharrague P et al. Inflammatory/haematopoietic cytokine production by human bone marrow adipocytes. Eur. Cytokine Netw., 2000, 11: 634-639

[258] Sanchez-Lopez E et al. Choline uptake and metabolism modulate macrophage IL-1β and IL-18 production. Cell Metab., 2019, 29: 1350-1362.e7

[259] Romas E et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J. Exp. Med., 1996, 183: 2581-2591

[260] Ishimi Y et al. IL-6 is produced by osteoblasts and induces bone resorption. J. Immunol., 1990, 145: 3297-3303

[261] Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin. Exp. Metastasis, 2015, 32: 353-368

[262] Cereijo R et al. CXCL14, a brown adipokine that mediates brown-fat-to-macrophage communication in thermogenic adaptation. Cell Metab., 2018, 28: 750-763.e6

[263] Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol., 2010, 10: 170-181

[264] Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J. Exp. Med., 2020, 217

[265] Li P et al. Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell, 2016, 167: 973-984.e12

[266] Lyons JJ et al. ERBIN deficiency links STAT3 and TGF-β pathway defects with atopy in humans. J. Exp. Med., 2017, 214: 669-680

[267] Rajbhandari P et al. IL-10 signaling remodels adipose chromatin architecture to limit thermogenesis and energy expenditure. Cell, 2018, 172: 218-233.e17

[268] Corre J et al. Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors. J. Cell Physiol., 2006, 208: 282-288

[269] Cawthorn WP et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab., 2014, 20: 368-375

[270] Rendina-Ruedy E, Rosen CJ. Lipids in the bone marrow: an evolving perspective. Cell Metab., 2020, 31: 219-231

[271] Kricun ME. Red-yellow marrow conversion: its effect on the location of some solitary bone lesions. Skelet. Radio., 1985, 14: 10-19

[272] Tavassoli M. Marrow adipose cells. Histochemical identification of labile and stable components. Arch. Pathol. Lab Med, 1976, 100: 16-18

[273] Nishio M et al. Production of functional classical brown adipocytes from human pluripotent stem cells using specific hemopoietin cocktail without gene transfer. Cell Metab., 2012, 16: 394-406

[274] Wang ZV, Scherer PE. Adiponectin, the past two decades. J. Mol. Cell Biol., 2016, 8: 93-100

[275] Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 1995, 270: 26746-26749

[276] Scheller EL, Burr AA, MacDougald OA, Cawthorn WP. Inside out: bone marrow adipose tissue as a source of circulating adiponectin. Adipocyte, 2016, 5: 251-269

[277] Gil-Campos M, Cañete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr., 2004, 23: 963-974

[278] Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab., 2013, 17: 185-196

[279] Yamauchi T et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423: 762-769

[280] Yamauchi T et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 2001, 7: 941-946

[281] Stanford KI et al. 12,13-diHOME: an exercise-induced lipokine that increases skeletal muscle fatty acid uptake. Cell Metab., 2018, 27: 1111-1120.e3

[282] Manieri E et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J. Exp. Med., 2019, 216: 1108-1119

[283] González A, Hall MN, Lin SC, Hardie DG. AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control. Cell Metab., 2020, 31: 472-492

[284] Qi Y et al. Adiponectin acts in the brain to decrease body weight. Nat. Med., 2004, 10: 524-529

[285] Uchihashi K et al. Organotypic culture of human bone marrow adipose tissue. Pathol. Int., 2010, 60: 259-267

[286] Berner HS et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone, 2004, 35: 842-849

[287] Dalamaga M et al. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab., 2013, 18: 29-42

[288] Hoggard N et al. Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridization. Biochem. Biophys. Res. Commun., 1997, 232: 383-387

[289] Harris RBS. Direct and indirect effects of leptin on adipocyte metabolism. Biochim. Biophys. Acta., 2014, 1842: 414-423

[290] Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature, 1999, 401: 73-76

[291] Alfa RW et al. Suppression of insulin production and secretion by a decretin hormone. Cell Metab., 2018, 27: 479

[292] Zhao S et al. Partial leptin reduction as an insulin sensitization and weight loss strategy. Cell Metab., 2019, 30: 706-719.e6

[293] Müller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J. Biol. Chem., 1997, 272: 10585-10593

[294] Laharrague P et al. High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J., 1998, 12: 747-752

[295] Krings A et al. Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes. Bone, 2012, 50: 546-552

[296] Laharrague P et al. Regulation by cytokines of leptin expression in human bone marrow adipocytes. Horm. Metab. Res., 2000, 32: 381-385

[297] Münzberg H, Heymsfield SB. New insights into the regulation of leptin gene expression. Cell Metab., 2019, 29: 1013-1014

[298] Upadhyay J, Farr OM, Mantzoros CS. The role of leptin in regulating bone metabolism. Metabolism, 2015, 64: 105-113

[299] Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor signalling. Nat. Rev. Mol. Cell Biol., 2018, 19: 31-44

[300] Pramojanee SN, Phimphilai M, Chattipakorn N, Chattipakorn SC. Possible roles of insulin signaling in osteoblasts. Endocr. Res., 2014, 39: 144-151

[301] Fulzele K et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell, 2010, 142: 309-319

[302] Fulzele K et al. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem., 2007, 282: 25649-25658

[303] Oh JH, Lee NK. Up-regulation of RANK expression via ERK1/2 by insulin contributes to the enhancement of osteoclast differentiation. Mol. Cells, 2017, 40: 371-377

[304] Shimoaka T et al. Impairment of bone healing by insulin receptor substrate-1 deficiency. J. Biol. Chem., 2004, 279: 15314-15322

[305] Conte C, Epstein S, Napoli N. Insulin resistance and bone: a biological partnership. Acta Diabetol., 2018, 55: 305-314

[306] Li Z et al. Glucose transporter-4 facilitates insulin-stimulated glucose uptake in osteoblasts. Endocrinology, 2016, 157: 4094-4103

[307] Ferron M et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell, 2010, 142: 296-308

[308] Mera P et al. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. Cell Metab., 2017, 25: 218

[309] Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev., 2016, 96: 365-408

[310] Hochberg Z, Tiosano D, Even L. Calcium therapy for calcitriol-resistant rickets. J. Pediatr., 1992, 121: 803-808

[311] Erben RG et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol. Endocrinol., 2002, 16: 1524-1537

[312] Nakamichi Y et al. VDR in osteoblast-lineage cells primarily mediates vitamin D treatment-induced increase in bone mass by suppressing bone resorption. J. Bone Min. Res., 2017, 32: 1297-1308

[313] Matthews DG, D’Angelo J, Drelich J, Welsh J. Adipose-specific Vdr deletion alters body fat and enhances mammary epithelial density. J. Steroid Biochem. Mol. Biol., 2016, 164: 299-308

[314] Rosenstreich SJ, Rich C, Volwiler W. Deposition in and release of vitamin D3 from body fat: evidence for a storage site in the rat. J. Clin. Investig., 1971, 50: 679-687

[315] Abbas MA. Physiological functions of Vitamin D in adipose tissue. J. Steroid Biochem Mol. Biol., 2017, 165: 369-381

[316] Blumberg JM et al. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J. Biol. Chem., 2006, 281: 11205-11213

[317] Ricciardi CJ et al. 1,25-Dihydroxyvitamin D3/vitamin D receptor suppresses brown adipocyte differentiation and mitochondrial respiration. Eur. J. Nutr., 2015, 54: 1001-1012

[318] Sun X, Zemel MB. Role of uncoupling protein 2 (UCP2) expression and 1alpha, 25-dihydroxyvitamin D3 in modulating adipocyte apoptosis. FASEB J., 2004, 18: 1430-1432

[319] Eshraghian A. Bone metabolism in non-alcoholic fatty liver disease: vitamin D status and bone mineral density. Minerva Endocrinol., 2017, 42: 164-172

[320] Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care, 2007, 30: 980-986

[321] Liu S et al. Bovine parathyroid hormone enhances osteoclast bone resorption by modulating V-ATPase through PTH1R. Int J. Mol. Med., 2016, 37: 284-292

[322] Guo J et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab., 2010, 11: 161-171

[323] Vrahnas C et al. Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation. Bone, 2016, 93: 146-154

[324] Jilka RL et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Investig., 1999, 104: 439-446

[325] Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone, 2005, 37: 148-158

[326] Boucher D et al. Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity. J. Exp. Med., 2018, 215: 827-840

[327] Esen E, Lee S-Y, Wice BM, Long F. PTH promotes bone anabolism by stimulating aerobic glycolysis via IGF signaling. J. Bone Min. Res., 2015, 30: 1959-1968

[328] Yamaguchi M. Effect of parathyroid hormone on the increase in serum glucose and insulin levels after a glucose load to thyroparathyroidectomized rats. Endocrinol. Jpn, 1979, 26: 353-358

[329] Kimura S, Sasase T, Ohta T, Sato E, Matsushita M. Parathyroid hormone (1-34) improves bone mineral density and glucose metabolism in Spontaneously Diabetic Torii-Lepr(fa) rats. J. Vet. Med. Sci., 2012, 74: 103-105

[330] Chiu KC et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism, 2000, 49: 1501-1505

[331] Heuck CC, Ritz E. Does parathyroid hormone play a role in lipid metabolism? Contrib. Nephrol., 1980, 20: 118-128

[332] Lacour B, Basile C, Drüeke T, Funck-Brentano JL. Parathyroid function and lipid metabolism in the rat. Min. Electrolyte Metab., 1982, 7: 157-165

[333] Larsson S, Jones HA, Göransson O, Degerman E, Holm C. Parathyroid hormone induces adipocyte lipolysis via PKA-mediated phosphorylation of hormone-sensitive lipase. Cell Signal, 2016, 28: 204-213

[334] LeBlanc ME et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J. Exp. Med., 2017, 214: 1029-1047

[335] Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol. Metab., 2011, 22: 24-33

[336] Jia M, Dahlman-Wright K, Gustafsson J-Å. Estrogen receptor alpha and beta in health and disease. Best. Pr. Res Clin. Endocrinol. Metab., 2015, 29: 557-568

[337] Brown LM, Gent L, Davis K, Clegg DJ. Metabolic impact of sex hormones on obesity. Brain Res., 2010, 1350: 77-85

[338] Voisin DL, Simonian SX, Herbison AE. Identification of estrogen receptor-containing neurons projecting to the rat supraoptic nucleus. Neuroscience, 1997, 78: 215-228

[339] Xu Y et al. Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction. Cell Metab., 2019, 29: 1232

[340] Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N. Engl. J. Med., 1989, 320: 1060-1068

[341] Cooke PS, Naaz A. Role of estrogens in adipocyte development and function. Exp. Biol. Med., 2004, 229: 1127-1135

[342] Gorres BK, Bomhoff GL, Morris JK, Geiger PC. In vivo stimulation of oestrogen receptor α increases insulin-stimulated skeletal muscle glucose uptake. J. Physiol., 2011, 589: 2041-2054

[343] Hayashi M et al. Autoregulation of osteocyte Sema3A orchestrates estrogen action and counteracts bone aging. Cell Metab., 2019, 29: 627-637.e5

[344] Kondoh S et al. Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice. Bone, 2014, 60: 68-77

[345] Novack DV. Estrogen and bone: osteoclasts take center stage. Cell Metab., 2007, 6: 254-256

[346] Streicher C et al. Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci. Rep., 2017, 7: 6460

[347] Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am. J. Epidemiol., 2007, 166: 495-505

[348] Schwartz AV et al. Older women with diabetes have an increased risk of fracture: a prospective study. J. Clin. Endocrinol. Metab., 2001, 86: 32-38

[349] Evans AL, Paggiosi MA, Eastell R, Walsh JS. Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J. Bone Min. Res, 2015, 30: 920-928

[350] Sornay-Rendu E, Boutroy S, Vilayphiou N, Claustrat B, Chapurlat RD. In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight: the Os des Femmes de Lyon (OFELY) study. J. Bone Min. Res, 2013, 28: 1679-1687

[351] Driessler F, Baldock PA. Hypothalamic regulation of bone. J. Mol. Endocrinol., 2010, 45: 175-181

[352] Lin YY et al. Adiponectin receptor 1 regulates bone formation and osteoblast differentiation by GSK-3β/β-catenin signaling in mice. Bone, 2014, 64: 147-154

[353] Boskey AL, Coleman R. Aging and bone. J. Dent. Res, 2010, 89: 1333-1348

[354] Grandl G, Wolfrum C. Adipocytes at the core of bone function. Cell Stem Cell, 2017, 20: 739-740

[355] Benedetti MG, Furlini G, Zati A, Letizia Mauro G. The effectiveness of physical exercise on bone density in osteoporotic patients. Biomed. Res. Int., 2018, 2018: 4840531

[356] Contrepois K et al. Molecular choreography of acute exercise. Cell, 2020, 181: 1112-1130.e16

[357] Horowitz AM et al. Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain. Science, 2020, 369: 167-173

[358] Duan P, Yang M, Wei M, Liu J, Tu P. Serum osteoprotegerin is a potential biomarker of insulin resistance in chinese postmenopausal women with prediabetes and type 2 diabetes. Int J. Endocrinol., 2017, 2017: 8724869

[359] Ndip A, Wilkinson FL, Jude EB, Boulton AJM, Alexander MY. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. Diabetologia, 2014, 57: 2251-2260

[360] Cypess AM, Haft CR, Laughlin MR, Hu HH. Brown fat in humans: consensus points and experimental guidelines. Cell Metab., 2014, 20: 408-415

[361] Yao Q et al. Wnt/β-catenin signaling in osteoblasts regulates global energy metabolism. Bone, 2017, 97: 175-183

[362] Wang P et al. Osthole promotes bone fracture healing through activation of BMP signaling in chondrocytes. Int J. Biol. Sci., 2017, 13: 996-1007

[363] Yee CS et al. Conditional deletion of Sost in MSC-derived lineages identifies specific cell-type contributions to bone mass and B-cell development. J. Bone Min. Res, 2018, 33: 1748-1759